Manufacturing Partnerships Revolo has engaged a contract manufacturing organization (Northway Biotech) to manufacture 1805, signaling readiness to scale production for development and potential early commercialization. This track record can support outreach for additional manufacturing, process development, and supply agreements with prospective partners seeking end-to-end CDMO services.

Clinical Collaborations With two drug candidates in clinical development and a disease-agnostic mechanism, Revolo is well positioned for co-development, trial collaborations, or research partnerships with pharmaceutical companies and CROs. Plan targeted outreach around upcoming conferences such as AAAAI and WAO, focusing on immunology, rheumatology, gastroenterology, and allergy audiences to explore indications expansion.

Strategic Funding The company has secured notable funding and is generating early revenue, reflecting investor confidence and initial market traction. These signals can facilitate licensing conversations for 1805 or 1104, as well as co-development deals that help accelerate clinical milestones and expand the pipeline reach.

Indication Opportunity Current and planned indications include 1805 for rheumatoid arthritis and non-infectious uveitis, and 1104 for eosinophilic esophagitis and allergic diseases. This broad, multi-indication portfolio supports a cross-specialty sales approach targeting rheumatology, ophthalmology, gastroenterology, and allergy clinics, with a unified narrative around a disease-agnostic immune reset platform.

Leadership Credibility Industry experience in leadership and board appointments enhances credibility with potential large-pharma partners, CMOs, and academic collaborators. Use this governance expertise in initial BD outreach to establish trust and accelerate discussions around licensing, collaborations, or strategic investments.